An up-dated meta-analysis of major adverse cardiac events on triple versus dual antiplatelet therapy after percutaneous coronary intervention in patients with type 2 diabetes mellitus
Mao Liu,
Wenjing Lu,
Ling Chen,
Yanmei Wang,
Zhuoling Zhao,
Mei Zhang,
Weiwei Du,
Zhan Lv
Affiliations
Mao Liu
Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China; Cardiovascular Research Center, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, PR China; Corresponding author at: Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China.
Wenjing Lu
Department of Cardiology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, PR China
Ling Chen
Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China; Cardiovascular Research Center, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, PR China
Yanmei Wang
Department of Clinical Medicine, Yaan Polytechnic College, Yaan 625000, PR China
Zhuoling Zhao
Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China
Mei Zhang
Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China
Weiwei Du
Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China
Zhan Lv
Department of Cardiology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, PR China; Cardiovascular Research Center, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, PR China
This meta-analysis is conducted to assess the efficiency and safety of triple antiplatelet therapy in patients with type 2 diabetes mellitus (T2DM) who have received coronary stents implantation. The risk of major adverse cardiac events (MACEs), target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI) and bleeding events were evaluated in this meta-analysis. Eight randomized controlled trials incorporating 1700 participants were included. During a follow-up of 12 months after stents implantation, the risk of TVR, TLR and MACEs in Triple group were lower than that of Dual group. There was no significant difference in the comparison of stent thrombosis and bleeding events between the two groups. Triple antiplatelet therapy is effective in reducing adverse cardiovascular outcomes in T2DM patients after stents implantation, without increasing the risk of bleeding events. Advanced designed and large-scale trails are deserved in the future.
